Skip to main content

M16-123 An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotypes 1 - 6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotypes 1 - 6 Chronic Hepatitis C Virus (HCV) Infection

Associated Conditions

Infectious Disease

Principal Investigator

Sponsor

AbbVie

The purpose of this study is to measure study drug levels in the bloodstream of children who are between the ages of 3 to 17 years old at the time of enrollment and to determine if the study drugs are safe and able to reduce the amount of hepatitis C virus (HCV) in the blood.